Is Aducanumab In Alzheimer’s A Candidate For Medicare ‘Coverage With Evidence Development’?

Medicare may look to bolster evidence on Biogen’s potential Alzheimer’s treatment, if approved, with a national coverage decision requiring the collection of clinical data in the postmarket setting.

Aducanumab Could Set A Precedent For Medicare Coverage Of Alzheimer's Drugs

Medicare could require Biogen, Inc. and Eisai Co., Ltd. to collect clinical data on the use and effectiveness of aducanumab in Alzheimer’s disease as a condition of coverage if the drug is approved by the US Food and Drug Administration.

Coverage with evidence development offers a way for Medicare to manage aducanumab’s high potential cost in light of questions that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet